메뉴 건너뛰기




Volumn 26, Issue 4, 2010, Pages 849-860

Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension

Author keywords

Angiotensin receptor blocker; Costs; Healthcare utilization; Hypertension; Switching; Valsartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; VALSARTAN; VASODILATOR AGENT;

EID: 77949519771     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003613910     Document Type: Article
Times cited : (16)

References (67)
  • 1
    • 33846857559 scopus 로고    scopus 로고
    • Heart disease and stroke statistics-2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
    • Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171
    • (2007) Circulation , vol.115
    • Rosamond, W.1    Flegal, K.2    Friday, G.3
  • 2
    • 33746305637 scopus 로고    scopus 로고
    • Incremental expenditure of treating hypertension in the United States
    • Balu S, Thomas J. Incremental expenditure of treating hypertension in the United States. Am J Hypertens 2006;19:810-816
    • (2006) Am J Hypertens , vol.19 , pp. 810-816
    • Balu, S.1    Thomas, J.2
  • 3
    • 56749174059 scopus 로고    scopus 로고
    • Blood pressure control and phar-macotherapy patterns in the United States before and after the release of the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7) Guidelines
    • Jackson JH, Sobolski J, Krienke R, et al. Blood pressure control and phar-macotherapy patterns in the United States before and after the release of the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7) Guidelines. J Am Board Fam Med 2008; 21:512-521
    • (2008) J Am Board Fam Med , vol.21 , pp. 512-521
    • Jackson, J.H.1    Sobolski, J.2    Krienke, R.3
  • 4
    • 0347423198 scopus 로고    scopus 로고
    • Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
    • Chobanian AV. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252
    • (2003) Hypertension , vol.42 , pp. 1206-1252
    • Chobanian, A.V.1
  • 5
    • 0032417173 scopus 로고    scopus 로고
    • Changes in antihypertensive therapy-the role of adverse effects and compliance
    • Dü sing R, Weisser B, Mengden T, et al. Changes in antihypertensive therapy-the role of adverse effects and compliance. Blood Press 1998;7:313-315
    • (1998) Blood Press , vol.7 , pp. 313-315
    • Dü Sing, R.W.1
  • 6
    • 3142777139 scopus 로고    scopus 로고
    • Medication adherence: A key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients
    • Krousel-Wood M, Thomas S, Muntner P, et al. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357-362
    • (2004) Curr Opin Cardiol , vol.19 , pp. 357-362
    • Krousel-Wood, M.1    Thomas, S.2    Muntner, P.3
  • 7
    • 67650503176 scopus 로고    scopus 로고
    • Better adherence to antihypertensive agents and risk reduction of chronic heart failure
    • Perreault S, Dragomir A, White M, et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med 2009; 266:207-218
    • (2009) J Intern Med , vol.266 , pp. 207-218
    • Perreault, S.1    Dragomir, A.2    White, M.3
  • 8
    • 60549087524 scopus 로고    scopus 로고
    • Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention
    • Kettani FZ, Dragomir A, Cote R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009;40:213-220
    • (2009) Stroke , vol.40 , pp. 213-220
    • Kettani, F.Z.1    Dragomir, A.2    Cote, R.3
  • 9
    • 38149027829 scopus 로고    scopus 로고
    • The economic consequences of noncompliance in cardiovascular disease and related conditions: A literature review
    • Muszbek N, Brixner D, Benedict A, et al. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract 2008;62:338-351
    • (2008) Int J Clin Pract , vol.62 , pp. 338-351
    • Muszbek, N.1    Brixner, D.2    Benedict, A.3
  • 10
    • 0031427407 scopus 로고    scopus 로고
    • Variations in compliance among hypertensive patients by drug class: Implications for health care costs
    • Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997; 19:1446-1457
    • (1997) Clin Ther , vol.19 , pp. 1446-1457
    • Rizzo, J.A.1    Simons, W.R.2
  • 11
    • 0036672238 scopus 로고    scopus 로고
    • A population-based European cohort study of persistence in newly diagnosed hypertensive patients
    • Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569-575
    • (2002) J Hum Hypertens , vol.16 , pp. 569-575
    • Hasford, J.1    Mimran, A.2    Simons, W.R.3
  • 12
    • 0031659477 scopus 로고    scopus 로고
    • Continuation of initial antihypertensive medication after 1 year of therapy
    • Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-681
    • (1998) Clin Ther , vol.20 , pp. 671-681
    • Bloom, B.S.1
  • 13
    • 77949522281 scopus 로고    scopus 로고
    • Novartis International AG Press Release, April 21 [Last accessed 9 February 2009]
    • Novartis International AG Press Release, April 21 2008. Available at: http:// www.marketwire.com/press-release/Novartis-International-Ag-845918.html [Last accessed 9 February 2009]
    • (2008)
  • 14
    • 77949533650 scopus 로고    scopus 로고
    • The pharmacokinetics of angiotensin II receptor blockers (ARBs): Are they different?
    • Zusman RM. The pharmacokinetics of angiotensin II receptor blockers (ARBs): Are they different? Am J Hypertens 1998;11:258A
    • (1998) Am J Hypertens , vol.11
    • Zusman, R.M.1
  • 15
    • 0035852724 scopus 로고    scopus 로고
    • Angiotensin II type 1 receptor blockers
    • Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103: 904-912
    • (2001) Circulation , vol.103 , pp. 904-912
    • Burnier, M.1
  • 17
    • 55049136834 scopus 로고    scopus 로고
    • Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension (Review)
    • Heran BS, Wong MMY, Heran IK, et al. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension (Review). Cochrane Database Syst Rev 2008;157pp
    • (2008) Cochrane Database Syst Rev
    • Heran, B.S.1    Wong, M.M.Y.2    Heran, I.K.3
  • 18
    • 0036894727 scopus 로고    scopus 로고
    • Irbesartan substitution for valsartan or losartan in treating hypertension
    • Graham MR, Allcock NM. Irbesartan substitution for valsartan or losartan in treating hypertension. Ann Pharmacother 2002;36:1840-1844
    • (2002) Ann Pharmacother , vol.36 , pp. 1840-1844
    • Graham, M.R.1    Allcock, N.M.2
  • 19
    • 0032899960 scopus 로고    scopus 로고
    • A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension
    • Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999;12:414-417
    • (1999) Am J Hypertens , vol.12 , pp. 414-417
    • Hedner, T.1    Oparil, S.2    Rasmussen, K.3
  • 20
    • 64149092737 scopus 로고    scopus 로고
    • Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: A meta-analytical approach
    • Nixon RM, Mü ller E, Lowy A, et al. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract 2009;63:766-775
    • (2009) Int J Clin Pract , vol.63 , pp. 766-775
    • Nixon, R.M.1    Müller, E.L.2
  • 21
    • 0036528691 scopus 로고    scopus 로고
    • An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angio-tensin II receptor antagonists, irbesartan and valsartan
    • Mancia G, Korlipara K, Van Rossum P, et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angio-tensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7:135-142
    • (2002) Blood Press Monit , vol.7 , pp. 135-142
    • Mancia, G.1    Korlipara, K.2    Van Rossum, P.3
  • 22
    • 0033945064 scopus 로고    scopus 로고
    • Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan
    • Losartan Trial Investigators
    • Monterosso VH, Rodriguez Chavez V, Carbajal ET, et al. Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators. Adv Ther 2000;17:117-131
    • (2000) Adv Ther , vol.17 , pp. 117-131
    • Monterosso, V.H.1    Rodriguez Chavez, V.2    Carbajal, E.T.3
  • 23
    • 0034760610 scopus 로고    scopus 로고
    • Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension
    • 318
    • Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3:283-91,318
    • (2001) J Clin Hypertens (Greenwich) , vol.3 , pp. 283-91
    • Oparil, S.1    Williams, D.2    Chrysant, S.G.3
  • 24
    • 2342512836 scopus 로고    scopus 로고
    • Olmesartan compared with other angiotensin II receptor antagonists: Head-to-head trials
    • Stumpe KO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther 2004;26:A33-37
    • (2004) Clin Ther , vol.26
    • Stumpe, K.O.1
  • 25
    • 67649449128 scopus 로고    scopus 로고
    • Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: The EX-STAND study
    • Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens 2009;23:479-489
    • (2009) J Hum Hypertens , vol.23 , pp. 479-489
    • Flack, J.M.1    Calhoun, D.A.2    Satlin, L.3
  • 26
    • 0037225198 scopus 로고    scopus 로고
    • Financial and health costs of uncontrolled blood pressure in the United Kingdom
    • Lloyd A, Schmieder C, Marchant N, et al. Financial and health costs of uncontrolled blood pressure in the United Kingdom. Pharmacoeconomics 2003;21:33-41
    • (2003) Pharmacoeconomics , vol.21 , pp. 33-41
    • Lloyd, A.1    Schmieder, C.2    Marchant, N.3
  • 27
    • 24944578450 scopus 로고    scopus 로고
    • Epidemiology of uncontrolled hypertension in the United States
    • Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 2005;112:1651-1662
    • (2005) Circulation , vol.112 , pp. 1651-1662
    • Wang, T.J.1    Vasan, R.S.2
  • 28
    • 77949511773 scopus 로고    scopus 로고
    • NDA 20-898/S-026 Atacand (Candesartan cilexetil) Tablets. Astra Zeneca website [Last accessed 9 February 2009]
    • NDA 20-898/S-026 Atacand (Candesartan cilexetil) Tablets. Astra Zeneca website. Available at: http://www1.astrazeneca-us.com/pi/Atacand.pdf [Last accessed 9 February 2009]
  • 29
    • 77949523947 scopus 로고    scopus 로고
    • NDA 20-757/S-038 Avapro (irbesartan) Tablets. FDA approved drug products. Washington, DC: FDA/Center for Drug Evaluation and Research [Last accessed 9 February 2009]
    • NDA 20-757/S-038 Avapro (irbesartan) Tablets. FDA approved drug products. Washington, DC: FDA/Center for Drug Evaluation and Research. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/ 020757s038lbl.pdf [Last accessed 9 February 2009]
  • 30
    • 77949524971 scopus 로고    scopus 로고
    • NDA 21-286/S-010 Benicar (Olmesartan medoxomil) Tablets. FDA approved drug products. Washington, DC: FDA/Center for Drug Evaluation and Research [Last accessed 9 February 2009]
    • NDA 21-286/S-010 Benicar (Olmesartan medoxomil) Tablets. FDA approved drug products. Washington, DC: FDA/Center for Drug Evaluation and Research. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2005/021286s010lbl.pdf [Last accessed 9 February 2009]
  • 31
    • 77949524243 scopus 로고    scopus 로고
    • NDA 20-386/S-045 Cozaar (Losartan potassium) Tablets. Merck website [Last accessed 9 February 2009]
    • NDA 20-386/S-045 Cozaar (Losartan potassium) Tablets. Merck website. Available at: http://www.merck.com/product/usa/pi-circulars/c/cozaar/ cozaar-pi.pdf [Last accessed 9 February 2009]
  • 32
    • 77949522943 scopus 로고    scopus 로고
    • NDA 20-850/S-013 Micardis (Telmisartan) Tablets. FDA approved drug products. Washington, DC: FDA/Center for Drug Evaluation and Research [Last accessed 9 February 2009]
    • NDA 20-850/S-013 Micardis (Telmisartan) Tablets. FDA approved drug products. Washington, DC: FDA/Center for Drug Evaluation and Research. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/ 020850s013lbl.pdf [Last accessed 9 February 2009]
  • 33
    • 49149087718 scopus 로고    scopus 로고
    • Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial
    • Mann JFE, Schmieder RE, Queen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547-553
    • (2008) Lancet , vol.372 , pp. 547-553
    • Mann, J.F.E.1    Schmieder, R.E.2    Queen, M.3
  • 34
    • 38849113845 scopus 로고    scopus 로고
    • Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on
    • Usher-Smith J, Ramsbottom T, Pearmain H, et al. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008;62:480-484
    • (2008) Int J Clin Pract , vol.62 , pp. 480-484
    • Usher-Smith, J.1    Ramsbottom, T.2    Pearmain, H.3
  • 35
    • 47949097809 scopus 로고    scopus 로고
    • Switch strategies in the management of hypertension: A cost minimisation analysis of angiotensin receptor blocker based regimen
    • Besley JD. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen. Curr Med Res Opin 2008;24:1975-1989
    • (2008) Curr Med Res Opin , vol.24 , pp. 1975-1989
    • Besley, J.D.1
  • 36
    • 77949524473 scopus 로고    scopus 로고
    • Diovan (valsartan) Tablets. Novartis Pharmaceuticals Corporation website [Last accessed 9 February 2009]
    • Diovan (valsartan) Tablets. Novartis Pharmaceuticals Corporation website. Available at: www.pharma.us.novartis.com/product/pi/pdf/diovan.pdf [Last accessed 9 February 2009]
  • 37
    • 44949209595 scopus 로고    scopus 로고
    • Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study)
    • Leidig M, Bambauer R, Kirchertz EJ, et al. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Clin Nephrol 2008; 69:425-432
    • (2008) Clin Nephrol , vol.69 , pp. 425-432
    • Leidig, M.1    Bambauer, R.2    Kirchertz, E.J.3
  • 38
    • 64249096233 scopus 로고    scopus 로고
    • Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy
    • Sinkiewicz W, Glazer RD, Kavoliuniene A, et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy. Curr Med Res Opin 2009; 25:315-324
    • (2009) Curr Med Res Opin , vol.25 , pp. 315-324
    • Sinkiewicz, W.1    Glazer, R.D.2    Kavoliuniene, A.3
  • 39
    • 42549113198 scopus 로고    scopus 로고
    • Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: A 6-month interim analysis
    • Chrysant SG, Murray AV, Hoppe UC, et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin 2008;24: 1039-1047
    • (2008) Curr Med Res Opin , vol.24 , pp. 1039-1047
    • Chrysant, S.G.1    Murray, A.V.2    Hoppe, U.C.3
  • 40
    • 33745698991 scopus 로고    scopus 로고
    • Randomized, double-blind, crossover comparison of amlodipine and valsartan in African-Americans with hypertension using 24-hour ambulatory blood pressure monitoring
    • Maciejewski S, Mohiuddin SM, Packard KA, et al. Randomized, double-blind, crossover comparison of amlodipine and valsartan in African-Americans with hypertension using 24-hour ambulatory blood pressure monitoring. Pharmacotherapy 2006;26:889-895
    • (2006) Pharmacotherapy , vol.26 , pp. 889-895
    • MacIejewski, S.1    Mohiuddin, S.M.2    Packard, K.A.3
  • 41
    • 0036384291 scopus 로고    scopus 로고
    • Valsartan/hydrochlorothiazide: A review of its pharmacology, therapeutic efficacy and place in the management of hypertension
    • Wellington K, Faulds DM. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 2002;62:1983-2005
    • (2002) Drugs , vol.62 , pp. 1983-2005
    • Wellington, K.1    Faulds, D.M.2
  • 42
    • 0036866158 scopus 로고    scopus 로고
    • The safety of valsartan: Results of a postmarketing surveillance study on 12881 patients in England
    • Biswas PN, Wilton LV, Shakir SW, et al. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England. J Hum Hypertens 2002;16:795-803
    • (2002) J Hum Hypertens , vol.16 , pp. 795-803
    • Biswas, P.N.1    Wilton, L.V.2    Shakir, S.W.3
  • 44
    • 84949193513 scopus 로고
    • Reducing bias in observational studies using subclassification on the propensity score
    • Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-524
    • (1984) J Am Stat Assoc , vol.79 , pp. 516-524
    • Rosenbaum, P.R.1    Rubin, D.B.2
  • 45
    • 77951622706 scopus 로고
    • The central role of the propensity score in observational studies for causal effects
    • Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
    • (1983) Biometrika , vol.70 , pp. 41-55
    • Rosenbaum, P.R.1    Rubin, D.B.2
  • 46
    • 1542742319 scopus 로고    scopus 로고
    • Combining propensity score matching with additional adjustments for prognostic covariates
    • Rubin DB, Thomas N. Combining propensity score matching with additional adjustments for prognostic covariates. J Am Stat Assoc 2000; 95:573-585
    • (2000) J Am Stat Assoc , vol.95 , pp. 573-585
    • Rubin, D.B.1    Thomas, N.2
  • 48
    • 0014297593 scopus 로고
    • The effectiveness of adjustment by subclassification in removing bias in observational studies
    • Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics 1968;24:295-313
    • (1968) Biometrics , vol.24 , pp. 295-313
    • Cochran, W.G.1
  • 49
    • 35148825449 scopus 로고    scopus 로고
    • Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease
    • Johnson RJ, Segal MS, Sautin Y, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 2007; 86:899-906
    • (2007) Am J Clin Nutr , vol.86 , pp. 899-906
    • Johnson, R.J.1    Segal, M.S.2    Sautin, Y.3
  • 50
    • 0029103037 scopus 로고
    • Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population
    • Jones JK, Gorkin L, Lian JF, et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995;311:293-295
    • (1995) BMJ , vol.311 , pp. 293-295
    • Jones, J.K.1    Gorkin, L.2    Lian, J.F.3
  • 51
    • 14844311192 scopus 로고    scopus 로고
    • Medicaid prescription drug access restrictions: Exploring the effect on patient persistence with hypertension medications
    • Wilson J, Axelsen K, Tang S, et al. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care 2005;11:SP27-34
    • (2005) Am J Manag Care , vol.11
    • Wilson, J.1    Axelsen, K.2    Tang, S.3
  • 52
    • 67649388476 scopus 로고    scopus 로고
    • Clinical review: Impact of statin substitution policies on patient outcomes
    • Atar D, Carmena R, Clemmensen P, et al. Clinical review: impact of statin substitution policies on patient outcomes. Ann Med 2009;41:242-256
    • (2009) Ann Med , vol.41 , pp. 242-256
    • Atar, D.1    Carmena, R.2    Clemmensen, P.3
  • 53
    • 33746385061 scopus 로고    scopus 로고
    • Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization
    • Meissner B, Dickson M, Shinogle J, et al. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. Manag Care Pharm 2006; 12:331-340
    • (2006) Manag Care Pharm , vol.12 , pp. 331-340
    • Meissner, B.1    Dickson, M.2    Shinogle, J.3
  • 54
    • 48449100823 scopus 로고    scopus 로고
    • Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder
    • Khandker RK, Kruzikas DT, McLaughlin TP, et al. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder. J Manag Care Pharm 2008;14:426-441
    • (2008) J Manag Care Pharm , vol.14 , pp. 426-441
    • Khandker, R.K.1    Kruzikas, D.T.2    McLaughlin, T.P.3
  • 55
    • 61849112140 scopus 로고    scopus 로고
    • Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes
    • Zachry WM, Doan QD, Clewell JD, et al. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009;50:493-500
    • (2009) Epilepsia , vol.50 , pp. 493-500
    • Zachry, W.M.1    Doan, Q.D.2    Clewell, J.D.3
  • 56
    • 0038460302 scopus 로고    scopus 로고
    • The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report
    • Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-2572
    • (2003) JAMA , vol.289 , pp. 2560-2572
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3
  • 57
    • 33644811462 scopus 로고    scopus 로고
    • High prevalence of newly detected hypertension in hospitalized patients: The value of in-hospital 24-h blood pressure measurement
    • Conen D, Martina B, Perruchoud AP, et al. High prevalence of newly detected hypertension in hospitalized patients: the value of in-hospital 24-h blood pressure measurement. J Hypertens 2006;24:301-306
    • (2006) J Hypertens , vol.24 , pp. 301-306
    • Conen, D.1    Martina, B.2    Perruchoud, A.P.3
  • 58
    • 0031757393 scopus 로고    scopus 로고
    • Asymptomatic hypertension in the ED
    • Chiang WK, Jamshahi B. Asymptomatic hypertension in the ED. Am J Emerg Med 1998;16:701-704
    • (1998) Am J Emerg Med , vol.16 , pp. 701-704
    • Chiang, W.K.1    Jamshahi, B.2
  • 59
    • 0036460172 scopus 로고    scopus 로고
    • Management of patients with hypertensive urgencies and emergencies: A systematic review of the literature
    • Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med 2002;17:937-945
    • (2002) J Gen Intern Med , vol.17 , pp. 937-945
    • Cherney, D.1    Straus, S.2
  • 60
    • 0024439418 scopus 로고
    • Rapid reduction of severe asymptomatic hypertension. A prospective, controlled trial
    • Zeller KR, Von Kuhnert L, Matthews C, et al. Rapid reduction of severe asymptomatic hypertension. A prospective, controlled trial. Arch Intern Med 1989;149:2186-2189
    • (1989) Arch Intern Med , vol.149 , pp. 2186-2189
    • Zeller, K.R.1    Von Kuhnert, L.2    Matthews, C.3
  • 61
    • 41149134763 scopus 로고    scopus 로고
    • Impact of multitiered copayments on the use and cost of prescription drugs among Medicare beneficiaries
    • Gilman BH, Kautter J. Impact of multitiered copayments on the use and cost of prescription drugs among Medicare beneficiaries. Health Serv Res 2008; 43:478-495
    • (2008) Health Serv Res , vol.43 , pp. 478-495
    • Gilman, B.H.1    Kautter, J.2
  • 62
    • 34247887485 scopus 로고    scopus 로고
    • Estimating the effects of prescription drug coverage for Medicare beneficiaries
    • Shea DG, Terza JV, Stuart BC, et al. Estimating the effects of prescription drug coverage for Medicare beneficiaries. Health Serv Res 2007;42:933-949
    • (2007) Health Serv Res , vol.42 , pp. 933-949
    • Shea, D.G.1    Terza, J.V.2    Stuart, B.C.3
  • 63
    • 27344453213 scopus 로고    scopus 로고
    • Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization
    • Landsman PB, Yu W, Liu XF, et al. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care 2005;11:621-628
    • (2005) Am J Manag Care , vol.11 , pp. 621-628
    • Landsman, P.B.1    Yu, W.2    Liu, X.F.3
  • 64
    • 0028387858 scopus 로고
    • Substitution laws, insurance coverage, and generic drug use
    • Anis AH. Substitution laws, insurance coverage, and generic drug use. Med Care 1994;32:240-256
    • (1994) Med Care , vol.32 , pp. 240-256
    • Anis, A.H.1
  • 65
    • 0036844349 scopus 로고    scopus 로고
    • Dutch GPs' perceptions: The influence of out-of-pocket costs on prescribing
    • Kasje WN, Timmer JW, Boendermaker PM, et al. Dutch GPs' perceptions: the influence of out-of-pocket costs on prescribing. Soc Sci Med 2002;55:1571-1578
    • (2002) Soc Sci Med , vol.55 , pp. 1571-1578
    • Kasje, W.N.1    Timmer, J.W.2    Boendermaker, P.M.3
  • 66
    • 0035818884 scopus 로고    scopus 로고
    • A Randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
    • Cohn JN, Tognoni G. A Randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675
    • (2001) N Engl J Med , vol.345 , pp. 1667-1675
    • Cohn, J.N.1    Tognoni, G.2
  • 67
    • 0242490542 scopus 로고    scopus 로고
    • Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    • Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906
    • (2003) N Engl J Med , vol.349 , pp. 1893-1906
    • Pfeffer, M.A.1    McMurray, J.J.V.2    Velazquez, E.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.